JP2017538680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538680A5 JP2017538680A5 JP2017525120A JP2017525120A JP2017538680A5 JP 2017538680 A5 JP2017538680 A5 JP 2017538680A5 JP 2017525120 A JP2017525120 A JP 2017525120A JP 2017525120 A JP2017525120 A JP 2017525120A JP 2017538680 A5 JP2017538680 A5 JP 2017538680A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer
- recurrence
- therapeutic agent
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 29
- 239000003814 drug Substances 0.000 claims 19
- 229940124597 therapeutic agent Drugs 0.000 claims 19
- 201000011510 cancer Diseases 0.000 claims 13
- 102000040430 polynucleotide Human genes 0.000 claims 13
- 108091033319 polynucleotide Proteins 0.000 claims 13
- 239000002157 polynucleotide Substances 0.000 claims 13
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 9
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 7
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 3
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 241000710960 Sindbis virus Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108091006082 receptor inhibitors Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075532P | 2014-11-05 | 2014-11-05 | |
| US62/075,532 | 2014-11-05 | ||
| PCT/US2015/059297 WO2016073759A1 (en) | 2014-11-05 | 2015-11-05 | Combination immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538680A JP2017538680A (ja) | 2017-12-28 |
| JP2017538680A5 true JP2017538680A5 (cg-RX-API-DMAC7.html) | 2018-12-13 |
| JP7305300B2 JP7305300B2 (ja) | 2023-07-10 |
Family
ID=55909820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525120A Active JP7305300B2 (ja) | 2014-11-05 | 2015-11-05 | 併用免疫療法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11236139B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3215182B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7305300B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016073759A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102000770B1 (ko) | 2011-12-01 | 2019-07-16 | 케모센트릭스, 인크. | Ｃｃｒ(4) 길항제로서의 치환된 아닐린 |
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| EP3215182B1 (en) | 2014-11-05 | 2023-01-04 | The Regents of The University of California | Combination immunotherapy |
| TWI716405B (zh) | 2015-05-07 | 2021-01-21 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
| RS63897B1 (sr) | 2015-05-29 | 2023-02-28 | Bristol Myers Squibb Co | Antitela protiv ox40 i njihova primena |
| CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| JP7169195B2 (ja) * | 2016-05-20 | 2022-11-10 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
| HUE065176T2 (hu) | 2016-06-02 | 2024-05-28 | Ultimovacs Asa | Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében |
| CN109476748B (zh) * | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| EP3684792A1 (en) | 2017-09-21 | 2020-07-29 | The University of Copenhagen | Chemotaxis-potentiating peptides and uses thereof |
| WO2019217898A1 (en) * | 2018-05-10 | 2019-11-14 | The Regents Of The University Of California | Ccl21 and checkpoint inhibitors for the treatment of cancer |
| WO2020047030A1 (en) * | 2018-08-29 | 2020-03-05 | Chemocentryx, Inc. | Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors |
| US20220184040A1 (en) * | 2019-03-26 | 2022-06-16 | Translational Drug Development, Llc | Method of treating malignant rhabdoid tumor of the ovary and small cell cancer of the ovary of the hypercalcemic type |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| WO1991004282A1 (fr) | 1989-09-21 | 1991-04-04 | Idemitsu Kosan Co., Ltd. | Polymere et copolymere d'arylstyrene et procede de preparation de tels polymeres |
| AU2147192A (en) | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| US20030175801A1 (en) | 2001-04-18 | 2003-09-18 | Dubinett Steven M. | Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| KR20050107399A (ko) | 2003-01-23 | 2005-11-11 | 오노 야꾸힝 고교 가부시키가이샤 | 인간 ｐｄ-1에 대하여 특이성을 갖는 물질 |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US20110059137A1 (en) | 2008-03-21 | 2011-03-10 | H. Lee Moffitt Cancer Center And Research Institutute, Inc | Chemokine gene-modified cells for cancer immunotherapy |
| WO2010029435A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| JP6257607B2 (ja) * | 2012-06-08 | 2018-01-10 | アデュロ バイオテック，インコーポレイテッド | 癌免疫療法のための組成物および方法 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| EP3215182B1 (en) | 2014-11-05 | 2023-01-04 | The Regents of The University of California | Combination immunotherapy |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| WO2017151524A1 (en) | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods and systems for evaluating tumor mutational burden |
| AU2018251898A1 (en) * | 2017-04-13 | 2019-10-31 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| WO2019217898A1 (en) | 2018-05-10 | 2019-11-14 | The Regents Of The University Of California | Ccl21 and checkpoint inhibitors for the treatment of cancer |
-
2015
- 2015-11-05 EP EP15856689.3A patent/EP3215182B1/en active Active
- 2015-11-05 JP JP2017525120A patent/JP7305300B2/ja active Active
- 2015-11-05 US US15/524,740 patent/US11236139B2/en active Active
- 2015-11-05 WO PCT/US2015/059297 patent/WO2016073759A1/en not_active Ceased
-
2022
- 2022-01-18 US US17/577,973 patent/US20220162279A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538680A5 (cg-RX-API-DMAC7.html) | ||
| Hilmi et al. | Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? | |
| Croce et al. | The multifaceted anti-cancer effects of BRAF-inhibitors | |
| Van Limbergen et al. | Combining radiotherapy with immunotherapy: the past, the present and the future | |
| JP2018502120A5 (cg-RX-API-DMAC7.html) | ||
| Van der Jeught et al. | Targeting the tumor microenvironment to enhance antitumor immune responses | |
| Procaccio et al. | Immunotherapy in gastrointestinal cancers | |
| Tartour et al. | Lung cancer: potential targets for immunotherapy | |
| IL318946A (en) | Combinations of checkpoint inhibitors and cancer drugs | |
| JP2019504892A5 (cg-RX-API-DMAC7.html) | ||
| Weiner | Cancer immunology for the clinician | |
| FI3728313T3 (fi) | Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä | |
| JP2020505342A5 (cg-RX-API-DMAC7.html) | ||
| JP2016527286A5 (cg-RX-API-DMAC7.html) | ||
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP7146739B2 (ja) | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ | |
| HK1249433A1 (zh) | 含有mk2抑制剂肽的组合物用於治疗非小细胞肺癌的用途 | |
| Tagliamonte et al. | Potentiating cancer vaccine efficacy in liver cancer | |
| JP2018023397A5 (cg-RX-API-DMAC7.html) | ||
| JP2012196206A5 (cg-RX-API-DMAC7.html) | ||
| JP2019517508A5 (cg-RX-API-DMAC7.html) | ||
| JP2017530130A5 (cg-RX-API-DMAC7.html) | ||
| Murthy et al. | Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy | |
| Giavedoni et al. | Acne fulminans successfully treated with cyclosporine and isotretinoin | |
| Rallis et al. | Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances |